GHRH analogue
Sermorelin updates
Answer
2 changes for Sermorelin in the last 12 months. Latest: 2025-11-20.
| Date | Type | What changed | Source |
|---|---|---|---|
| 2025-11-20 | Results | Results posted: Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | Trial register ClinicalTrials.gov |
| 2025-10-15 | Recall | FDA recall, Class II: GenoGenix LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2024-08-15 | Trial | New trial registered: Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV | Trial register ClinicalTrials.gov |
| 2023-12-04 | Action | California Board of Pharmacy: board | Regulator California Board of Pharmacy |
| 2022-11-16 | Results | Results posted: Adult Growth Hormone Deficiency and Cardiovascular Risk | Trial register ClinicalTrials.gov |
| 2022-09-21 | Recall | FDA recall, Class II: Carolina Infusion. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2022-07-20 | Recall | FDA recall, Class II: TMC Acquisition LLC dba Tailor Made Compounding. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2022-07-20 | Recall | FDA recall, Class II: TMC Acquisition LLC dba Tailor Made Compounding. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2022-07-20 | Recall | FDA recall, Class II: TMC Acquisition LLC dba Tailor Made Compounding. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2022-06-01 | Recall | FDA recall, Class II: Olympia Compounding Pharmacy dba Olympia Pharmacy. Lack of assurance of sterility. | Regulator FDA enforcement reports |
| 2022-05-04 | Recall | FDA recall, Class II: Olympia Compounding Pharmacy dba Olympia Pharmacy. CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action L | Regulator FDA enforcement reports |
| 2022-04-27 | Recall | FDA recall, Class II: North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding. Lack of Assurance of Sterility: deviations from Current Good Manu | Regulator FDA enforcement reports |
| 2022-03-30 | Recall | FDA recall, Class II: Olympia Compounding Pharmacy dba Olympia Pharmacy. Sub Potent | Regulator FDA enforcement reports |
| 2020-01-13 | Results | Results posted: Tesamorelin Effects on Liver Fat and Histology in HIV | Trial register ClinicalTrials.gov |
| 2019-11-06 | Recall | FDA recall, Class II: Innoveix Pharmaceuticals Inc. Lack of Sterility Assurance. | Regulator FDA enforcement reports |
| 2019-10-09 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2019-10-09 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2019-10-09 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2019-10-09 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2019-10-09 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2019-10-09 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2019-10-09 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2019-10-09 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2019-07-09 | Results | Results posted: The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure | Trial register ClinicalTrials.gov |
| 2019-06-19 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Sterility Assurance. | Regulator FDA enforcement reports |
| 2019-06-19 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Sterility Assurance. | Regulator FDA enforcement reports |
| 2019-06-19 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Sterility Assurance. | Regulator FDA enforcement reports |
| 2019-06-19 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Sterility Assurance. | Regulator FDA enforcement reports |
| 2019-06-19 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Sterility Assurance. | Regulator FDA enforcement reports |
| 2019-05-24 | Results | Results posted: Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly | Trial register ClinicalTrials.gov |
| 2019-04-24 | Recall | FDA recall, Class II: Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-04-24 | Recall | FDA recall, Class II: Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2018-11-07 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2018-11-07 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2018-11-07 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2018-11-07 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2018-11-07 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2018-03-21 | Recall | FDA recall, Class II: American Pharmaceutical Ingredients LLC. Stability Data Does Not Support Expiry: Stability data from manufacturer does not support expiration dates | Regulator FDA enforcement reports |
| 2018-01-17 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredie | Regulator FDA enforcement reports |
| 2018-01-17 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredie | Regulator FDA enforcement reports |
| 2018-01-17 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredie | Regulator FDA enforcement reports |
| 2018-01-17 | Recall | FDA recall, Class II: KRS Global Biotechnology, Inc. Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredie | Regulator FDA enforcement reports |
| 2017-12-18 | Trial | New trial registered: Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | Trial register ClinicalTrials.gov |
| 2017-04-27 | Results | Results posted: Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly | Trial register ClinicalTrials.gov |
| 2017-01-25 | Trial | New trial registered: Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers | Trial register ClinicalTrials.gov |
| 2017-01-11 | Recall | FDA recall, Class II: Tri-Coast Pharmacy. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Tri-Coast Pharmacy. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Tri-Coast Pharmacy. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Tri-Coast Pharmacy. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-11 | Recall | FDA recall, Class II: Wells Pharmacy Network LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2017-01-06 | Trial | New trial registered: Diagnosing Adult Growth Hormone Deficiency | Trial register ClinicalTrials.gov |
| 2016-08-31 | Recall | FDA recall, Class II: Talon Compounding Pharmacy. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2016-04-08 | Trial | New trial registered: Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response | Trial register ClinicalTrials.gov |
| 2015-12-09 | Recall | FDA recall, Class II: Western Drug. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2015-11-25 | Recall | FDA recall, Class II: Kalman Health & Wellness, Inc. dba Essential Wellness Pharma. Lack of Assurance of Sterility: A recall of all compounded sterile preparations withi | Regulator FDA enforcement reports |
| 2015-11-25 | Recall | FDA recall, Class II: Kalman Health & Wellness, Inc. dba Essential Wellness Pharma. Lack of Assurance of Sterility: A recall of all compounded sterile preparations withi | Regulator FDA enforcement reports |
| 2015-11-25 | Recall | FDA recall, Class II: Kalman Health & Wellness, Inc. dba Essential Wellness Pharma. Lack of Assurance of Sterility: A recall of all compounded sterile preparations withi | Regulator FDA enforcement reports |
| 2015-10-14 | Recall | FDA recall, Class II: Diabetes Corporation of America dba DCA Pharmacy. Lack of Assurance of Sterility: A recent FDA inspection found that this product was not being comp | Regulator FDA enforcement reports |
| 2015-09-23 | Recall | FDA recall, Class II: The Compounding Pharmacy of America. Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality | Regulator FDA enforcement reports |
| 2015-09-23 | Recall | FDA recall, Class II: The Compounding Pharmacy of America. Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality | Regulator FDA enforcement reports |
| 2015-09-23 | Recall | FDA recall, Class II: The Compounding Pharmacy of America. Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality | Regulator FDA enforcement reports |
| 2015-09-23 | Recall | FDA recall, Class II: The Compounding Pharmacy of America. Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality | Regulator FDA enforcement reports |
| 2015-09-23 | Recall | FDA recall, Class II: The Compounding Pharmacy of America. Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality | Regulator FDA enforcement reports |
| 2015-09-03 | Trial | New trial registered: The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment | Trial register ClinicalTrials.gov |
| 2015-06-03 | Trial | New trial registered: Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD) | Trial register ClinicalTrials.gov |
| 2014-10-17 | Trial | New trial registered: Estradiol-Receptor Blockade in Older Men and Women | Trial register ClinicalTrials.gov |
| 2014-10-13 | Results | Results posted: Effects of Growth Hormone Releasing Hormone in HIV | Trial register ClinicalTrials.gov |
| 2014-07-22 | Trial | New trial registered: Tesamorelin Effects on Liver Fat and Histology in HIV | Trial register ClinicalTrials.gov |
| 2014-01-15 | Results | Results posted: TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy | Trial register ClinicalTrials.gov |
| 2014-01-08 | Results | Results posted: Effects of Short-term Growth Hormone in HIV-infected Patients | Trial register ClinicalTrials.gov |
| 2013-12-16 | Trial | New trial registered: Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients | Trial register ClinicalTrials.gov |
| 2013-12-11 | Recall | FDA recall, Class II: Main Street Family Pharmacy, LLC. The firm received seven reports of adverse reactions in the form of skin abscesses potentially linked to compounde | Regulator FDA enforcement reports |
| 2013-12-11 | Recall | FDA recall, Class II: Main Street Family Pharmacy, LLC. The firm received seven reports of adverse reactions in the form of skin abscesses potentially linked to compounde | Regulator FDA enforcement reports |
| 2013-12-11 | Recall | FDA recall, Class II: Main Street Family Pharmacy, LLC. The firm received seven reports of adverse reactions in the form of skin abscesses potentially linked to compounde | Regulator FDA enforcement reports |
| 2013-12-11 | Recall | FDA recall, Class II: Main Street Family Pharmacy, LLC. The firm received seven reports of adverse reactions in the form of skin abscesses potentially linked to compounde | Regulator FDA enforcement reports |
| 2013-09-18 | Recall | FDA recall, Class II: Beacon Hill Medical Pharmacy, P.C.. Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control p | Regulator FDA enforcement reports |
| 2013-07-17 | Recall | FDA recall, Class II: Lowlite Investments, Inc. D/B/A Olympia Pharmacy. Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality con | Regulator FDA enforcement reports |
| 2013-03-04 | Federal Register | Federal Register notice: Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) In | Regulator Federal Register |
| 2013-01-07 | Results | Results posted: Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese | Trial register ClinicalTrials.gov |
| 2012-08-22 | Recall | FDA recall, Class II: Franck's Lab Inc., d.b.a. Franck's Compounding Lab. Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs | Regulator FDA enforcement reports |
| 2012-07-03 | Trial | New trial registered: Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue | Trial register ClinicalTrials.gov |
| 2011-06-17 | Trial | New trial registered: Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly | Trial register ClinicalTrials.gov |
| 2011-05-13 | Trial | New trial registered: VRS-317 in Adult Subjects With Growth Hormone Deficiency | Trial register ClinicalTrials.gov |
| 2011-03-30 | Results | Results posted: Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men | Trial register ClinicalTrials.gov |
| 2010-12-21 | Trial | New trial registered: Effects of Growth Hormone Releasing Hormone in HIV | Trial register ClinicalTrials.gov |
| 2010-01-29 | Trial | New trial registered: Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency | Trial register ClinicalTrials.gov |
The 100 newest of 113 are listed.
From ClinicalTrials.gov, EU CTIS, FDA labels, recalls, shortages and warning letters, the Federal Register, and regulators' published actions. Not medical advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.